INC Research Holdings Inc (INCR) was Initiated by Credit Suisse to “Outperform” and the brokerage firm has set the Price Target at $51. Credit Suisse advised their investors in a research report released on Jun 21, 2016.
Many Wall Street Analysts have commented on INC Research Holdings Inc. Shares were Downgraded by Robert W. Baird on May 3, 2016 to ” Neutral” and Lowered the Price Target to $ 51 from a previous price target of $55 .JP Morgan Initiated INC Research Holdings Inc on Mar 24, 2016 to “Overweight”, Price Target of the shares are set at $47.
On the company’s financial health, INC Research Holdings Inc reported $0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 2, 2016. Analyst had a consensus of $0.54. The company had revenue of $249.00 million for the quarter, compared to analysts expectations of $238.28 million. The company’s revenue was up 17.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.42 EPS.
INC Research Holdings Inc opened for trading at $37.71 and hit $38.49 on the upside on Monday, eventually ending the session at $38.185, with a gain of 2.07% or 0.775 points. The heightened volatility saw the trading volume jump to 8,69,728 shares. Company has a market cap of $2,070 M.
In a different news, on Jun 16, 2016, Christopher L Gaenzle (CAO, GC & Sec) sold 7,702 shares at $40.13 per share price. According to the SEC, on Jun 7, 2016, Michael Gibertini (President Clinical Development) sold 213,966 shares at $43.45 per share price. On Jun 3, 2016, Robert W Breckon (director) sold 11,691 shares at $43.52 per share price, according to the Form-4 filing with the securities and exchange commission.
INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.